ESTRO 2025 - Abstract Book

S4001

Radiobiology - Tumour radiobiology

ESTRO 2025

Conclusion: Treatment with Mito-PEG-ATO did not affect the fraction of hypoxia in MOC1.3D5 tumors. As MitoTam alleviates hypoxia in B16OVA and MC38 spheroids and demonstrated promising results in a recent clinical trial and was well tolerated with low toxicities, this OXPHOS inhibitor seems a promising candidate as hypoxia modifier and will be tested in the ongoing pre-clinical study.

Keywords: Hypoxia, mitochondria-targeting, OXPHOS